Lower clearance of sodium tanshinone IIA sulfonate in coronary heart disease patients and the effect of total bilirubin: a population pharmacokinetics analysis

Qin, Weiwei; Wang, Li; Jiao, Zheng; Wang, Bin; Wang, Chengyu; Qian, Lixuan; Qi, Wei; Zhong, Ming

doi:10.1016/s1875-5364(19)30024-x

Cited by 6 publications

(3 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…As shown in Figure 6, quercetin, kaempferol, luteolin, and tanshinone IIa were identi ed as representative compounds. Previous studies have reported that quercetin and kaempferol are avonoids from Zhizi and have biological activities against CHD such as anti-oxidation, anti-in ammation, inhibition of platelet activation, and relaxation of blood vessels [36]. Meanwhile, luteolin is a polyphenolic compound from Danshen, which exerts cardiovascular protective effects for the roles of reducing oxidative stress, and inhibiting in ammation and apoptosis [37].…”

Section: Discussionmentioning

confidence: 99%

A Network Pharmacology Analysis to Reveal the Molecular Mechanism of Zhizi-Danshen on Coronary Heart Disease

Shen¹,

Wang²,

Wu³

et al. 2020

Preprint

View full text Add to dashboard Cite

ObjectiveOur study aimed to investigate the potential mechanisms of the herb pair Zhizi-Danshen (ZD) for coronary heart disease (CHD) using network pharmacological data mining technology.MethodsThe Traditional Chinese Medicine System Pharmacology (TCMSP) database was used to collect the active ingredients of ZD and predict ZD-related target proteins. Afterwards, we identified CHD-related targets from DisGeNET database, NCBI gene database, and TTD database. The common targets both from ZD and CHD were screened by Venny2.1, which were then imported into the String database for protein-protein interaction (PPI) analysis. Finally, the GO and KEGG enrichment analysis were performed by R software, and the network construction was established using Cytoscape3.7.2.ResultsWe obtained 199 possible targets from 62 candidate ingredients of ZD and 1033 CHD-ralated targets, with 83 overlapping common target genes. Then, 11 core targets were acquired from PPI network analysis. Further, GO analysis showed that these common targets mainly influenced receptor ligand activity，cytokine activity，cytokine receptor binding，steroid hormone receptor activity, and peptide binding. KEGG pathway analysis indicated that ZD affected CHD through seven important pathways linked to vascular endothelial function regulation (fluid shear stress and atherosclerosis，AGE-RAGE signaling pathway in diabetic complications, HIF-1 signaling pathway), imflammatory effects (IL-17 signaling pathway, TNF signaling pathway，Toll-like receptor signaling pathway)，and hormone regulation (relaxin signaling pathway). ConclusionsThis study revealed the potential pharmacological mechanisms of ZD against CHD, which were mainly associated with regulation of vascular endothelial function and inflammatory effects, promotion of vasodilatation, and prevention of cardiac fibrosis. Moreover, it provided a novel conception for the development of alternative therapies on CHD.

show abstract

Section: Discussionmentioning

confidence: 99%

A Network Pharmacology Analysis to Reveal the Molecular Mechanism of Zhizi-Danshen on Coronary Heart Disease

Shen¹,

Wang²,

Wu³

et al. 2020

Preprint

View full text Add to dashboard Cite

show abstract

“…Shi et al found that the plasma concentrations of TSL, PCA, PAL, SAC, SAB, and TSIIA and the AUC 0−t , MRT 0−t, and t 1/2 of SAB and TSL in the middle cerebral artery occlusion rats were significantly increased compared with the sham-operated group (73). The CL of STS was lower in coronary heart disease patients than in healthy volunteers in a population pharmacokinetic model study (74). Moreover, several metabolites of TSIIA presented differences in the distribution between the sham control and the Alzherimer's Disease Rat model (75).…”

Section: The Bioavailability Of Danshen Compounds In Comparison Betwe...mentioning

confidence: 99%

Salvia miltiorrhiza Bge. (Danshen) in the Treating Non-alcoholic Fatty Liver Disease Based on the Regulator of Metabolic Targets

Liu

Shi

Peng

et al. 2022

Front. Cardiovasc. Med.

View full text Add to dashboard Cite

Non-alcoholic fatty liver disease (NAFLD) is rapidly prevalent due to its strong association with increased metabolic syndrome such as cardio- and cerebrovascular disorders and diabetes. Few drugs can meet the growing disease burden of NAFLD. Salvia miltiorrhiza Bge. (Danshen) have been used for over 2,000 years in clinical trials to treat NAFLD and metabolic syndrome disease without clarified defined mechanisms. Metabolic targets restored metabolic homeostasis in patients with NAFLD and improved steatosis by reducing the delivery of metabolic substrates to liver as a promising way. Here we systematic review evidence showing that Danshen against NAFLD through diverse and crossing mechanisms based on metabolic targets. A synopsis of the phytochemistry and pharmacokinetic of Danshen and the mechanisms of metabolic targets regulating the progression of NAFLD is initially provided, followed by the pharmacological activity of Danshen in the management NAFLD. And then, the possible mechanisms of Danshen in the management of NAFLD based on metabolic targets are elucidated. Specifically, the metabolic targets c-Jun N-terminal kinases (JNK), sterol regulatory element-binding protein-1c (SREBP-1c), nuclear translocation carbohydrate response element–binding protein (ChREBP) related with lipid metabolism pathway, and peroxisome proliferator-activated receptors (PPARs), cytochrome P450 (CYP) and the others associated with pleiotropic metabolism will be discussed. Finally, providing a critical assessment of the preclinic and clinic model and the molecular mechanism in NAFLD.

show abstract

“…Select 108 patients with HC-CHD who visited our hospital between January 2020 and June 2022, and split them into the general group and observation group, with 54 individuals in each group. Inclusion criteria: ① The clinical symptoms, electrocardiogram, cardiac ultrasound, coronary angiography and other examinations were in line with the relevant domestic and international guidelines for the diagnosis of CHD (3)(4)(5); ② With typical symptoms of angina pectoris, patients often feel chest compression, tightness and accompanied by dyspnea, fatigue, etc. ; ③ At the time of symptom attack, the electrocardiogram has transient ST segment change and T wave abnormality; ④ Medical image data showed segmental wall motion abnormalities; ⑤ Coronary angiography with Judkins method at least one coronary artery ≥ 50%; ⑥ Under the condition of a normal diet and purine diet, the blood uric acid level of male patients with non-two-day fasting blood uric acid level is more than 420μmol/L, female non-two-day This study was to observe the effect of Sodium TanshinoneⅡA Sulfonate (ST-ⅡAS) on blood uric acid (UA), human Soluble Intercellular Adhesion Molecule-1 (sICAM-1), Endothelin-1 (ET-1) and percentage of brachial artery Flow-Mediated Dilatation (FMD) in individuals with Hyperuricemia Complicated Coronary Heart Disease (HC-CHD).…”

Section: General Informationmentioning

confidence: 99%

Effect of Sodium Tanshinone ⅡA Sulfonate on uric acid, sicam-1, ET-1 and FMD in patients with coronary heart disease complicated with hyperuricemia

Yingli Wang,

Wenzong Zhou,

Jifeng Zhang

et al. 2023

Cell Mol Biol (Noisy-le-grand)

View full text Add to dashboard Cite

Lower clearance of sodium tanshinone IIA sulfonate in coronary heart disease patients and the effect of total bilirubin: a population pharmacokinetics analysis

Cited by 6 publications

References 24 publications

A Network Pharmacology Analysis to Reveal the Molecular Mechanism of Zhizi-Danshen on Coronary Heart Disease

A Network Pharmacology Analysis to Reveal the Molecular Mechanism of Zhizi-Danshen on Coronary Heart Disease

Salvia miltiorrhiza Bge. (Danshen) in the Treating Non-alcoholic Fatty Liver Disease Based on the Regulator of Metabolic Targets

Effect of Sodium Tanshinone ⅡA Sulfonate on uric acid, sicam-1, ET-1 and FMD in patients with coronary heart disease complicated with hyperuricemia

Contact Info

Product

Resources

About